---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-094126"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2023-08-22T23:59:59+00:00"
generated_at: "2026-06-11T05:30:35.895854+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences raises $20.4M in PIPE financing to fund clinical development

## Summary
- Gross proceeds of ~$20.4M from sale of common share units at $1.88/unit and pre-funded units at $1.87/unit.
- Participation from Affinity Asset Advisors, Ally Bridge Group, Sphera Healthcare and other accredited investors.
- Proceeds to advance clinical development of PMN310, lead therapeutic candidate, and for working capital.
- Insiders (directors and officers) subscribing for ~$145,000 of units under related party transaction exemptions.
- Financing expected to close on August 23, 2023.

## SEC filing metadata
- accession: 0001104659-23-094126
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2023-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465923094126/0001104659-23-094126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465923094126/tm2324315d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-094126
- JSON: https://secwatch.observer/filing/0001104659-23-094126.json
- Plain text: https://secwatch.observer/filing/0001104659-23-094126.txt

## Key facts
- Material Agreements
  ProMIS Neurosciences Inc. entered into Unit Purchase Agreement with selected investors that qualify as accredited investors valued at approximately $20.4 million (effective 2023-08-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: selected investors that qualify as accredited investors
  - Value: approximately $20.4 million
  - Effective: 2023-08-21
  source text: On August 21, 2023, ProMIS Neurosciences Inc. (the “ Company ”) entered into an Unit Purchase Agreement (the “ Unit Purchase Agreement ”) with selected investors that qualify as “accredited investors” (the “ PIPE Investors ”), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “ Securities Act ”), for the purpose of raising approximately $20.4 million in gross proceeds for the Company (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000110465923094126/0001104659-23-094126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.